Physician profile
Meghan Carr
NPI 1588271647
$6,624.10
in general payments reported to CMS, 2019-2025
17 companies · $2,806 in 2025
The $2,806 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $692 · 2022: $1,018 · 2023: $563 · 2024: $1,546 · 2025: $2,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,750 · Food and Beverage: $1,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,750.00 |
| Food and Beverage | $1,164.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,364.83 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $204.92 | 2021-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $187.07 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $139.09 | 2021 | |
| Lundbeck LLC | $108.76 | 2021-2022 | |
| Corium, LLC | $107.79 | 2024-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $101.16 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $78.80 | 2021-2022 | |
| Almatica Pharma LLC | $56.18 | 2022 | |
| Alkermes, INC. | $55.30 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $53.47 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.49 | 2022 | |
| Vanda Pharmaceuticals INC. | $38.41 | 2022 | |
| Idorsia Pharmaceuticals US INC | $29.64 | 2022-2024 | Quviviq |
| Alfasigma USA, INC. | $27.72 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $14.80 | 2021 | |
| Acadia Pharmaceuticals INC | $14.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.